Trials / Completed
CompletedNCT05034484
A Study of ALPN-303 in Adult Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Alpine Immune Sciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALPN-303 | Multiple dose levels will be evaluated. |
| DRUG | Placebo | Placebo will be administered |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2023-02-27
- Completion
- 2023-02-27
- First posted
- 2021-09-05
- Last updated
- 2023-05-09
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05034484. Inclusion in this directory is not an endorsement.